73731-86-9 Usage
Uses
Used in Pharmaceutical Industry:
Broussonin B is used as an anti-inflammatory agent for its potential to treat inflammatory diseases due to its anti-inflammatory properties.
Used in Anticancer Applications:
Broussonin B is used as an anti-cancer agent for its ability to inhibit the growth of various cancer cell lines, such as lung, liver, and breast cancer cells, thereby exhibiting potential in cancer treatment.
Used in Oxidative Stress Protection:
Broussonin B is used as an antioxidant to protect cells against oxidative stress-induced damage, highlighting its role in maintaining cellular health and potentially preventing diseases associated with oxidative stress.
Check Digit Verification of cas no
The CAS Registry Mumber 73731-86-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,7,3 and 1 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 73731-86:
(7*7)+(6*3)+(5*7)+(4*3)+(3*1)+(2*8)+(1*6)=139
139 % 10 = 9
So 73731-86-9 is a valid CAS Registry Number.
73731-86-9Relevant academic research and scientific papers
Concise synthesis of broussonone A
Jo, Hyeju,Choi, Minho,Viji, Mayavan,Lee, Young Hee,Kwak, Young-Shin,Lee, Kiho,Choi, Nam Song,Lee, Yeon-Ju,Lee, Heesoon,Hong, Jin Tae,Lee, Mi Kyeong,Jung, Jae-Kyung
, p. 15966 - 15975 (2015/12/01)
A concise and expeditious approach to the total synthesis of broussonone A, a p-quinol natural compound, has been developed. The key features of the synthesis include the Grubbs II catalyst mediated cross metathesis of two aromatic subunits, and a chemoselective oxidative dearomatizationin the presence of two phenol moieties. Especially, optimization associated with the CM reaction of ortho-alkoxystyrenes was also studied, which are known to be ineffective for Ru-catalyzed metathesis reactions under conventional reaction conditions because ortho-alkoxy group could coordinate to the ruthenium center, resulting in the potential complication of catalyst inhibition.
